Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase NA 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 99Myelodysplastic Syndromes 56Leukemia, Myelomonocytic, Chronic 23Leukemia 17Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 10Hematologic Neoplasms 9Multiple Myeloma 8Hodgkin Disease 8Neoplasms 6Myeloproliferative Disorders 6Leukemia, Myeloid 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Sarcoma 4Primary Myelofibrosis 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Biphenotypic, Acute 4Head and Neck Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

Cyclophosphamide 7fludarabine phosphate 6fludarabine 5Immunotherapy, Adoptive 3blinatumomab 2Cytarabine 2Azacitidine 2AP 1903 reagent 2venetoclax 1tisagenlecleucel 1ruxolitinib 1relugolix 1pulrodemstat besilate 1niraparib 1nilotinib 1enzalutamide 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Rituximab 1Radiotherapy 1NKTR-255 1Melphalan 1Injections 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Cetuximab 1CTL019 chimeric antigen receptor 1CD3 Complex 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm, Residual × Azacitidine × Clear all
NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Celgene

Phase 1 Terminated
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡